EB-001T and EB-001A To Be Spotlighted at The Aesthetic Meeting 2018
Bonti, Inc., an innovative clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin products for therapeutic and aesthetic applications, today announced a Hot Topics presentation for its therapeutic product candidate, EB-001T, and for its aesthetic product candidate, EB-001A, at the American Society for Aesthetic Plastic Surgery (ASAPS) The Aesthetic Meeting 2018, beginning April 26 in New York City, New York. EB-001, the active ingredient in both EB-001T and EB-001A, is derived from botulinum neurotoxin serotype E (BoNT/E) and is designed to have a clinical profile with a faster onset of efficacy (within 24 hours) and a shorter duration of activity (2 to 4 weeks) than botulinum neurotoxin serotype A (BoNT/A) products. EB-001T and EB-001A are being developed to address areas of unmet therapeutic and aesthetic need.
The Aesthetics Meeting 2018 Hot Topics presentation will be delivered by Dr. Alan Matarasso, a renowned aesthetic plastic surgeon and current Bonti Medical Advisor. It will feature BoNT/E as an innovative neurotoxin candidate for therapeutic and aesthetic applications. Highlights will include descriptions of the ongoing clinical trial of EB-001T in the mammoplasty model, the planned Phase 2 clinical trial of EB-001T in the abdominoplastly model and the ongoing Phase 2a clinical trial of EB-001A for scar reduction following Mohs micrographic surgery.
“We’re excited to have EB-001T and EB-001A presented at this prestigious conference in April as we continue to gather more data on these product candidates and further expand the scope of sharing the findings within the medical community,” said Fauad Hasan, CEO and co-founder at Bonti. “We appreciate the ASAPS for selecting EB-001T and EB-001A for this opportunity and are honored to have Dr. Matarasso share potential prospects of our product candidates with his colleagues.”
Bonti is developing a first-in-class pipeline of proprietary product candidates derived from BoNT/E. BoNT/E, from which the active ingredient in Bonti’s product candidates is derived, has a validated mechanism of action similar to that of currently approved products derived from BoNT/A, but, based on preclinical and clinical data, BoNT/E has a faster onset of efficacy (within 24 hours) and a shorter duration of activity (2 to 4 weeks) compared to BoNT/A products, which have an onset of efficacy of approximately 3 to 7 days and a duration of activity of approximately 3 to 4 months. Based on this differentiated clinical profile, Bonti’s therapeutic product candidate, EB-001T, is being developed for the treatment of focal muscle pain, and Bonti’s aesthetic product candidate, EB-001A, is being initially developed for glabellar frown lines and for scar reduction following Mohs surgery.
Bonti, based in Newport Beach, CA, is an innovative clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin products for therapeutic and aesthetic applications. The company was founded and is led by executives with extensive experience obtained at Allergan plc with botulinum neurotoxin products from discovery, clinical, supply chain, regulatory and commercialization perspectives. By turning the science of neurotoxins into beneficial patient and healthcare provider solutions, Bonti seeks to improve lives by successfully addressing key unmet needs in markets with significant addressable opportunities.
For more information, please visit http://bonti.com.